PubMed:22887862
Annnotations
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-125 | Sentence | denotes | Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. |
| T2 | 126-263 | Sentence | denotes | The presence of autoantibodies against immunoregulatory effectors can be relevant for onset and/or the progression of autoimmune disease. |
| T3 | 264-498 | Sentence | denotes | Emerging insights into an immunological activity profile including a role as opsonins give reason to systematically monitor sera of patients for immunoglobulin G (IgG) autoantibodies, preferably for several galectins at the same time. |
| T4 | 499-770 | Sentence | denotes | Here, we report on a study of chronic inflammatory rheumatic diseases, i.e. systemic lupus erythematosus (SLE; pilot cohort p, n = 40; confirmation cohort c, n = 109), rheumatoid arthritis (RA; p, n = 32; c, n = 25) and primary antiphospholipid syndrome (APS; c, n = 64). |
| T5 | 771-1004 | Sentence | denotes | Enzyme-linked immunosorbent assay-based series using galectin-1, -2, -3, -4, -7, -8 and -9 and natural processing products, i.e. the truncated version of galectin-3 and the N-terminal domains of galectin-4, -8 and -9, were performed. |
| T6 | 1005-1112 | Sentence | denotes | Normal healthy donors (p, n = 20; c, n = 21) and patients with paraproteins (c, n = 19) served as controls. |
| T7 | 1113-1307 | Sentence | denotes | Highly significant optical density-value readings for IgG autoantibodies were consistently detected for the proto-type galectin-7 (SLE) and the tandem repeat-type galectin-8 and -9 (SLE and RA). |
| T8 | 1308-1480 | Sentence | denotes | Their presence was independent from the autoantibody status against double-stranded DNA (for patients with SLE) or a rheumatoid factor (for patients with RA), respectively. |
| T9 | 1481-1685 | Sentence | denotes | Importantly, anti-galectin-2 autoantibodies highly significantly correlated with the appearance of a secondary APS in patients with SLE so that this parameter may serve as an additional biomarker for APS. |
| T10 | 1686-1893 | Sentence | denotes | Equally of note, the presence of IgG autoantibodies against galectins capable to act as an opsonin may contribute to a sustained immune dysregulation in patients with chronic inflammatory rheumatic diseases. |
| T1 | 0-125 | Sentence | denotes | Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. |
| T2 | 126-263 | Sentence | denotes | The presence of autoantibodies against immunoregulatory effectors can be relevant for onset and/or the progression of autoimmune disease. |
| T3 | 264-498 | Sentence | denotes | Emerging insights into an immunological activity profile including a role as opsonins give reason to systematically monitor sera of patients for immunoglobulin G (IgG) autoantibodies, preferably for several galectins at the same time. |
| T4 | 499-770 | Sentence | denotes | Here, we report on a study of chronic inflammatory rheumatic diseases, i.e. systemic lupus erythematosus (SLE; pilot cohort p, n = 40; confirmation cohort c, n = 109), rheumatoid arthritis (RA; p, n = 32; c, n = 25) and primary antiphospholipid syndrome (APS; c, n = 64). |
| T5 | 771-1004 | Sentence | denotes | Enzyme-linked immunosorbent assay-based series using galectin-1, -2, -3, -4, -7, -8 and -9 and natural processing products, i.e. the truncated version of galectin-3 and the N-terminal domains of galectin-4, -8 and -9, were performed. |
| T6 | 1005-1112 | Sentence | denotes | Normal healthy donors (p, n = 20; c, n = 21) and patients with paraproteins (c, n = 19) served as controls. |
| T7 | 1113-1307 | Sentence | denotes | Highly significant optical density-value readings for IgG autoantibodies were consistently detected for the proto-type galectin-7 (SLE) and the tandem repeat-type galectin-8 and -9 (SLE and RA). |
| T8 | 1308-1480 | Sentence | denotes | Their presence was independent from the autoantibody status against double-stranded DNA (for patients with SLE) or a rheumatoid factor (for patients with RA), respectively. |
| T9 | 1481-1685 | Sentence | denotes | Importantly, anti-galectin-2 autoantibodies highly significantly correlated with the appearance of a secondary APS in patients with SLE so that this parameter may serve as an additional biomarker for APS. |
| T10 | 1686-1893 | Sentence | denotes | Equally of note, the presence of IgG autoantibodies against galectins capable to act as an opsonin may contribute to a sustained immune dysregulation in patients with chronic inflammatory rheumatic diseases. |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-125 | Sentence | denotes | Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. |
| TextSentencer_T2 | 126-263 | Sentence | denotes | The presence of autoantibodies against immunoregulatory effectors can be relevant for onset and/or the progression of autoimmune disease. |
| TextSentencer_T3 | 264-498 | Sentence | denotes | Emerging insights into an immunological activity profile including a role as opsonins give reason to systematically monitor sera of patients for immunoglobulin G (IgG) autoantibodies, preferably for several galectins at the same time. |
| TextSentencer_T4 | 499-770 | Sentence | denotes | Here, we report on a study of chronic inflammatory rheumatic diseases, i.e. systemic lupus erythematosus (SLE; pilot cohort p, n = 40; confirmation cohort c, n = 109), rheumatoid arthritis (RA; p, n = 32; c, n = 25) and primary antiphospholipid syndrome (APS; c, n = 64). |
| TextSentencer_T5 | 771-1004 | Sentence | denotes | Enzyme-linked immunosorbent assay-based series using galectin-1, -2, -3, -4, -7, -8 and -9 and natural processing products, i.e. the truncated version of galectin-3 and the N-terminal domains of galectin-4, -8 and -9, were performed. |
| TextSentencer_T6 | 1005-1112 | Sentence | denotes | Normal healthy donors (p, n = 20; c, n = 21) and patients with paraproteins (c, n = 19) served as controls. |
| TextSentencer_T7 | 1113-1307 | Sentence | denotes | Highly significant optical density-value readings for IgG autoantibodies were consistently detected for the proto-type galectin-7 (SLE) and the tandem repeat-type galectin-8 and -9 (SLE and RA). |
| TextSentencer_T8 | 1308-1480 | Sentence | denotes | Their presence was independent from the autoantibody status against double-stranded DNA (for patients with SLE) or a rheumatoid factor (for patients with RA), respectively. |
| TextSentencer_T9 | 1481-1685 | Sentence | denotes | Importantly, anti-galectin-2 autoantibodies highly significantly correlated with the appearance of a secondary APS in patients with SLE so that this parameter may serve as an additional biomarker for APS. |
| TextSentencer_T10 | 1686-1893 | Sentence | denotes | Equally of note, the presence of IgG autoantibodies against galectins capable to act as an opsonin may contribute to a sustained immune dysregulation in patients with chronic inflammatory rheumatic diseases. |
| T1 | 0-125 | Sentence | denotes | Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. |
| T2 | 126-263 | Sentence | denotes | The presence of autoantibodies against immunoregulatory effectors can be relevant for onset and/or the progression of autoimmune disease. |
| T3 | 264-498 | Sentence | denotes | Emerging insights into an immunological activity profile including a role as opsonins give reason to systematically monitor sera of patients for immunoglobulin G (IgG) autoantibodies, preferably for several galectins at the same time. |
| T4 | 499-770 | Sentence | denotes | Here, we report on a study of chronic inflammatory rheumatic diseases, i.e. systemic lupus erythematosus (SLE; pilot cohort p, n = 40; confirmation cohort c, n = 109), rheumatoid arthritis (RA; p, n = 32; c, n = 25) and primary antiphospholipid syndrome (APS; c, n = 64). |
| T5 | 771-1004 | Sentence | denotes | Enzyme-linked immunosorbent assay-based series using galectin-1, -2, -3, -4, -7, -8 and -9 and natural processing products, i.e. the truncated version of galectin-3 and the N-terminal domains of galectin-4, -8 and -9, were performed. |
| T6 | 1005-1112 | Sentence | denotes | Normal healthy donors (p, n = 20; c, n = 21) and patients with paraproteins (c, n = 19) served as controls. |
| T7 | 1113-1307 | Sentence | denotes | Highly significant optical density-value readings for IgG autoantibodies were consistently detected for the proto-type galectin-7 (SLE) and the tandem repeat-type galectin-8 and -9 (SLE and RA). |
| T8 | 1308-1480 | Sentence | denotes | Their presence was independent from the autoantibody status against double-stranded DNA (for patients with SLE) or a rheumatoid factor (for patients with RA), respectively. |
| T9 | 1481-1685 | Sentence | denotes | Importantly, anti-galectin-2 autoantibodies highly significantly correlated with the appearance of a secondary APS in patients with SLE so that this parameter may serve as an additional biomarker for APS. |
| T10 | 1686-1893 | Sentence | denotes | Equally of note, the presence of IgG autoantibodies against galectins capable to act as an opsonin may contribute to a sustained immune dysregulation in patients with chronic inflammatory rheumatic diseases. |
| T1 | 0-125 | Sentence | denotes | Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. |
| T2 | 126-263 | Sentence | denotes | The presence of autoantibodies against immunoregulatory effectors can be relevant for onset and/or the progression of autoimmune disease. |
| T3 | 264-498 | Sentence | denotes | Emerging insights into an immunological activity profile including a role as opsonins give reason to systematically monitor sera of patients for immunoglobulin G (IgG) autoantibodies, preferably for several galectins at the same time. |
| T4 | 499-770 | Sentence | denotes | Here, we report on a study of chronic inflammatory rheumatic diseases, i.e. systemic lupus erythematosus (SLE; pilot cohort p, n = 40; confirmation cohort c, n = 109), rheumatoid arthritis (RA; p, n = 32; c, n = 25) and primary antiphospholipid syndrome (APS; c, n = 64). |
| T5 | 771-1004 | Sentence | denotes | Enzyme-linked immunosorbent assay-based series using galectin-1, -2, -3, -4, -7, -8 and -9 and natural processing products, i.e. the truncated version of galectin-3 and the N-terminal domains of galectin-4, -8 and -9, were performed. |
| T6 | 1005-1112 | Sentence | denotes | Normal healthy donors (p, n = 20; c, n = 21) and patients with paraproteins (c, n = 19) served as controls. |
| T7 | 1113-1307 | Sentence | denotes | Highly significant optical density-value readings for IgG autoantibodies were consistently detected for the proto-type galectin-7 (SLE) and the tandem repeat-type galectin-8 and -9 (SLE and RA). |
| T8 | 1308-1480 | Sentence | denotes | Their presence was independent from the autoantibody status against double-stranded DNA (for patients with SLE) or a rheumatoid factor (for patients with RA), respectively. |
| T9 | 1481-1685 | Sentence | denotes | Importantly, anti-galectin-2 autoantibodies highly significantly correlated with the appearance of a secondary APS in patients with SLE so that this parameter may serve as an additional biomarker for APS. |
| T10 | 1686-1893 | Sentence | denotes | Equally of note, the presence of IgG autoantibodies against galectins capable to act as an opsonin may contribute to a sustained immune dysregulation in patients with chronic inflammatory rheumatic diseases. |
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 244-254 | HP_0002960 | denotes | autoimmune |
| T2 | 244-262 | HP_0002960 | denotes | autoimmune disease |
| T3 | 575-603 | HP_0002725 | denotes | systemic lupus erythematosus |
| T4 | 667-687 | HP_0001370 | denotes | rheumatoid arthritis |
| T5 | 678-687 | HP_0001369 | denotes | arthritis |
| T6 | 1815-1835 | HP_0002958 | denotes | immune dysregulation |
ICD10
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 96-124 | http://purl.bioontology.org/ontology/ICD10/M32.9 | denotes | systemic lupus erythematosus |
| T2 | 575-603 | http://purl.bioontology.org/ontology/ICD10/M32.9 | denotes | systemic lupus erythematosus |
| T3 | 96-124 | http://purl.bioontology.org/ontology/ICD10/M32 | denotes | systemic lupus erythematosus |
| T4 | 575-603 | http://purl.bioontology.org/ontology/ICD10/M32 | denotes | systemic lupus erythematosus |
| T5 | 105-124 | http://purl.bioontology.org/ontology/ICD10/L93 | denotes | lupus erythematosus |
| T6 | 584-603 | http://purl.bioontology.org/ontology/ICD10/L93 | denotes | lupus erythematosus |
| T7 | 550-559 | http://purl.bioontology.org/ontology/ICD10/M79.0 | denotes | rheumatic |
| T8 | 1874-1883 | http://purl.bioontology.org/ontology/ICD10/M79.0 | denotes | rheumatic |
| T9 | 667-687 | http://purl.bioontology.org/ontology/ICD10/M06.9 | denotes | rheumatoid arthritis |
| T10 | 678-687 | http://purl.bioontology.org/ontology/ICD10/M13.9 | denotes | arthritis |
GlycoBiology-FMA
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| _T1 | 0-14 | FMAID:167180 | denotes | Autoantibodies |
| _T2 | 53-69 | FMAID:82779 | denotes | antiphospholipid |
| _T3 | 53-69 | FMAID:196772 | denotes | antiphospholipid |
| _T4 | 142-156 | FMAID:167180 | denotes | autoantibodies |
| _T5 | 409-423 | FMAID:167177 | denotes | immunoglobulin |
| _T6 | 409-423 | FMAID:62871 | denotes | immunoglobulin |
| _T7 | 409-425 | FMAID:167178 | denotes | immunoglobulin G |
| _T8 | 409-425 | FMAID:62872 | denotes | immunoglobulin G |
| _T9 | 409-425 | FMAID:167185 | denotes | immunoglobulin G |
| _T10 | 409-425 | FMAID:62875 | denotes | immunoglobulin G |
| _T11 | 409-425 | FMAID:167181 | denotes | immunoglobulin G |
| _T12 | 409-425 | FMAID:62873 | denotes | immunoglobulin G |
| _T13 | 409-425 | FMAID:62874 | denotes | immunoglobulin G |
| _T14 | 409-425 | FMAID:62876 | denotes | immunoglobulin G |
| _T15 | 409-425 | FMAID:167187 | denotes | immunoglobulin G |
| _T16 | 409-425 | FMAID:167183 | denotes | immunoglobulin G |
| _T17 | 427-430 | FMAID:167179 | denotes | IgG |
| _T18 | 432-446 | FMAID:167180 | denotes | autoantibodies |
| _T19 | 727-743 | FMAID:196772 | denotes | antiphospholipid |
| _T20 | 727-743 | FMAID:82779 | denotes | antiphospholipid |
| _T21 | 1167-1170 | FMAID:167179 | denotes | IgG |
| _T22 | 1171-1185 | FMAID:167180 | denotes | autoantibodies |
| _T23 | 1348-1360 | FMAID:167180 | denotes | autoantibody |
| _T24 | 1510-1524 | FMAID:167180 | denotes | autoantibodies |
| _T25 | 1719-1722 | FMAID:167179 | denotes | IgG |
| _T26 | 1723-1737 | FMAID:167180 | denotes | autoantibodies |
uniprot-human
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 754-757 | http://www.uniprot.org/uniprot/P07288 | denotes | APS |
| T2 | 1592-1595 | http://www.uniprot.org/uniprot/P07288 | denotes | APS |
| T3 | 1681-1684 | http://www.uniprot.org/uniprot/P07288 | denotes | APS |
| T4 | 754-757 | http://www.uniprot.org/uniprot/O14492 | denotes | APS |
| T5 | 1592-1595 | http://www.uniprot.org/uniprot/O14492 | denotes | APS |
| T6 | 1681-1684 | http://www.uniprot.org/uniprot/O14492 | denotes | APS |
| T7 | 824-834 | http://www.uniprot.org/uniprot/P09382 | denotes | galectin-1 |
| T8 | 925-935 | http://www.uniprot.org/uniprot/P17931 | denotes | galectin-3 |
| T9 | 966-976 | http://www.uniprot.org/uniprot/P56470 | denotes | galectin-4 |
| T10 | 1232-1242 | http://www.uniprot.org/uniprot/P47929 | denotes | galectin-7 |
| T11 | 1276-1286 | http://www.uniprot.org/uniprot/Q9H585 | denotes | galectin-8 |
| T12 | 1425-1442 | http://www.uniprot.org/uniprot/P04207 | denotes | rheumatoid factor |
| T13 | 1425-1442 | http://www.uniprot.org/uniprot/P04206 | denotes | rheumatoid factor |
| T14 | 1499-1509 | http://www.uniprot.org/uniprot/P05162 | denotes | galectin-2 |
uniprot-mouse
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 824-834 | http://www.uniprot.org/uniprot/P16045 | denotes | galectin-1 |
| T2 | 925-935 | http://www.uniprot.org/uniprot/P16110 | denotes | galectin-3 |
| T3 | 966-976 | http://www.uniprot.org/uniprot/Q8K419 | denotes | galectin-4 |
| T4 | 1232-1242 | http://www.uniprot.org/uniprot/O54974 | denotes | galectin-7 |
| T5 | 1276-1286 | http://www.uniprot.org/uniprot/Q9JL15 | denotes | galectin-8 |
| T6 | 1499-1509 | http://www.uniprot.org/uniprot/Q9CQW5 | denotes | galectin-2 |
GlycoBiology-NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 667-677 | http://purl.bioontology.org/ontology/NCBITAXON/572355 | denotes | rheumatoid |
| T2 | 1425-1435 | http://purl.bioontology.org/ontology/NCBITAXON/572355 | denotes | rheumatoid |
GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 388-392 | http://purl.obolibrary.org/obo/GO_0004617 | denotes | sera |
GO-MF
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 409-423 | http://purl.obolibrary.org/obo/GO_0003823 | denotes | immunoglobulin |
EDAM-topics
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 255-262 | http://edamontology.org/topic_0634 | denotes | disease |
| T2 | 290-303 | http://edamontology.org/topic_0804 | denotes | immunological |
| T3 | 520-525 | http://edamontology.org/topic_3678 | denotes | study |
| T4 | 560-568 | http://edamontology.org/topic_0634 | denotes | diseases |
| T5 | 946-954 | http://edamontology.org/topic_0749 | denotes | terminal |
| T6 | 1667-1676 | http://edamontology.org/topic_3360 | denotes | biomarker |
| T7 | 1884-1892 | http://edamontology.org/topic_0634 | denotes | diseases |
EDAM-DFO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 508-514 | http://edamontology.org/data_2048 | denotes | report |
| T2 | 874-884 | http://edamontology.org/operation_0004 | denotes | processing |
| T3 | 874-884 | http://edamontology.org/operation_2409 | denotes | processing |
| T4 | 1005-1011 | http://edamontology.org/operation_3435 | denotes | Normal |
| T5 | 1204-1212 | http://edamontology.org/operation_2423 | denotes | detected |
| T6 | 1383-1391 | http://edamontology.org/data_0853 | denotes | stranded |
| T7 | 1546-1556 | http://edamontology.org/operation_3465 | denotes | correlated |
| T8 | 1630-1639 | http://edamontology.org/data_2527 | denotes | parameter |
Allie
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| SS1_22887862_2_0 | 409-425 | expanded | denotes | immunoglobulin G |
| SS2_22887862_2_0 | 427-430 | abbr | denotes | IgG |
| SS1_22887862_3_0 | 575-603 | expanded | denotes | systemic lupus erythematosus |
| SS2_22887862_3_0 | 605-608 | abbr | denotes | SLE |
| SS1_22887862_3_1 | 667-687 | expanded | denotes | rheumatoid arthritis |
| SS2_22887862_3_1 | 689-691 | abbr | denotes | RA |
| SS1_22887862_3_2 | 727-752 | expanded | denotes | antiphospholipid syndrome |
| SS2_22887862_3_2 | 754-757 | abbr | denotes | APS |
| AE1_22887862_2_0 | SS1_22887862_2_0 | SS2_22887862_2_0 | abbreviatedTo | immunoglobulin G,IgG |
| AE1_22887862_3_0 | SS1_22887862_3_0 | SS2_22887862_3_0 | abbreviatedTo | systemic lupus erythematosus,SLE |
| AE1_22887862_3_1 | SS1_22887862_3_1 | SS2_22887862_3_1 | abbreviatedTo | rheumatoid arthritis,RA |
| AE1_22887862_3_2 | SS1_22887862_3_2 | SS2_22887862_3_2 | abbreviatedTo | antiphospholipid syndrome,APS |
Lectin
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| Lectin_T1 | 966-976 | https://acgg.asia/db/lfdb/LfDB0272 | denotes | galectin-4 |
| Lectin_T2 | 824-834 | https://acgg.asia/db/lfdb/LfDB0270 | denotes | galectin-1 |
| Lectin_T3 | 824-834 | https://acgg.asia/db/lfdb/LfDB0057 | denotes | galectin-1 |
mondo_disease
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 53-78 | Disease | denotes | antiphospholipid syndrome | http://purl.obolibrary.org/obo/MONDO_0007140 |
| T2 | 96-124 | Disease | denotes | systemic lupus erythematosus | http://purl.obolibrary.org/obo/MONDO_0007915 |
| T3 | 244-262 | Disease | denotes | autoimmune disease | http://purl.obolibrary.org/obo/MONDO_0007179 |
| T4 | 550-568 | Disease | denotes | rheumatic diseases | http://purl.obolibrary.org/obo/MONDO_0005554 |
| T5 | 575-603 | Disease | denotes | systemic lupus erythematosus | http://purl.obolibrary.org/obo/MONDO_0007915 |
| T6 | 605-608 | Disease | denotes | SLE | http://purl.obolibrary.org/obo/MONDO_0007915 |
| T7 | 667-687 | Disease | denotes | rheumatoid arthritis | http://purl.obolibrary.org/obo/MONDO_0008383 |
| T8 | 719-752 | Disease | denotes | primary antiphospholipid syndrome | http://purl.obolibrary.org/obo/MONDO_0005204 |
| T9 | 754-757 | Disease | denotes | APS | http://purl.obolibrary.org/obo/MONDO_0017278 |
| T10 | 1244-1247 | Disease | denotes | SLE | http://purl.obolibrary.org/obo/MONDO_0007915 |
| T11 | 1295-1298 | Disease | denotes | SLE | http://purl.obolibrary.org/obo/MONDO_0007915 |
| T12 | 1415-1418 | Disease | denotes | SLE | http://purl.obolibrary.org/obo/MONDO_0007915 |
| T13 | 1592-1595 | Disease | denotes | APS | http://purl.obolibrary.org/obo/MONDO_0017278 |
| T14 | 1613-1616 | Disease | denotes | SLE | http://purl.obolibrary.org/obo/MONDO_0007915 |
| T15 | 1681-1684 | Disease | denotes | APS | http://purl.obolibrary.org/obo/MONDO_0017278 |
| T16 | 1874-1892 | Disease | denotes | rheumatic diseases | http://purl.obolibrary.org/obo/MONDO_0005554 |
HP-phenotype
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 96-124 | Phenotype | denotes | systemic lupus erythematosus | HP:0002725 |
| T2 | 244-262 | Phenotype | denotes | autoimmune disease | HP:0002960 |
| T3 | 575-603 | Phenotype | denotes | systemic lupus erythematosus | HP:0002725 |
| T4 | 605-608 | Phenotype | denotes | SLE | HP:0002725 |
| T5 | 667-687 | Phenotype | denotes | rheumatoid arthritis | HP:0001370 |
| T6 | 689-691 | Phenotype | denotes | RA | HP:0001370 |
| T7 | 1244-1247 | Phenotype | denotes | SLE | HP:0002725 |
| T8 | 1295-1298 | Phenotype | denotes | SLE | HP:0002725 |
| T9 | 1303-1305 | Phenotype | denotes | RA | HP:0001370 |
| T10 | 1415-1418 | Phenotype | denotes | SLE | HP:0002725 |
| T11 | 1462-1464 | Phenotype | denotes | RA | HP:0001370 |
| T12 | 1613-1616 | Phenotype | denotes | SLE | HP:0002725 |
| T13 | 1815-1835 | Phenotype | denotes | immune dysregulation | HP:0002958 |